Targeted anticancer effect through microRNA-181a regulated tumor-specific hTERT replacement

Area of Science:

• Molecular Biology
• Gene Therapy
• Cancer Research

Background:

• Group I intron-based ribozymes can reprogram human telomerase reverse transcriptase (hTERT) RNA for cancer therapy.
• Targeting hTERT(+) cancer cells risks side effects in hTERT(+) hematopoietic stem cells.

Purpose of the Study:

• To enhance the specificity of ribozyme-mediated anti-cancer therapy.
• To mitigate potential side effects on hematopoietic cells.

Main Methods:

• Modified a previously developed ribozyme by incorporating target sites for microRNA-181a.
• Evaluated the modified ribozyme's specificity and efficacy in vitro and in a mouse model of liver cancer.

Main Results:

• The modified ribozyme demonstrated significantly improved specificity, targeting hTERT(+) cancer cells while sparing hematopoietic cells.
• The ribozyme effectively induced transgene expression and regressed liver tumors in a mouse model with minimal toxicity.
• Systemic delivery via adenoviral vector encoding the ribozyme was successful in vivo.

Conclusions:

• MicroRNA-regulated ribozymes offer a more precise approach for targeted RNA replacement in cancer therapy.
• This strategy enhances anti-cancer efficacy and safety by selectively targeting cancer cells.